XAIR Stock Forecast & Price Target

Beyond Air Inc. experienced a remarkable revenue increase of 157%, rising to $1.8 million in the quarter ended June 30, 2025, primarily driven by heightened demand for its LungFit PH system. The company reported a shift in its growth trajectory as gross profit turned positive at $0.2 million, showcasing enhanced commercial execution and operational efficiencies. Notably, a national group purchasing agreement with Premier, Inc. has unlocked access to over 4,350 hospitals, paving the way for accelerated adoption of its innovative nitric oxide delivery technology across both developed and emerging healthcare markets.

Beyond Air Inc. has reported a gross loss of $0.3 million, a decrease from $1.1 million a year prior, which, while showing improvement, highlights ongoing financial challenges faced by the company. The research and development (R&D) expenses have decreased to $2.5 million from $4.6 million, along with a reduced selling, general, and administrative (SG&A) expense of $4.9 million compared to $7.2 million, reflecting efforts to cut costs amidst persistent operating losses. The net loss for the period was $7.9 million, or $1.25 per share, indicating that despite reductions in expenses, the company continues to experience significant financial strain and high net cash burn of $4.7 million.